SND524

SND524 is a novel, plant-derived flavonoid derivative developed by Floratek Pharma in collaboration with the Institute of Oncology Research (IOR). It belongs to a series of modified flavonoid polyphenol scaffolds designed to overcome common limitations of natural flavonoids, such as low bioavailability and lack of specificity. SND524 acts as a potent microtubule-targeting agent (MTA) that promotes microtubule polymerization, a mechanism of action similar to that of taxanes. In preclinical studies presented at AACR 2024, SND524 demonstrated significant anti-proliferative activity in the nanomolar range (median IC50 of 46.7 nM) across various lymphoma models, including germinal center B-cell-like (GCB) and activated B-cell-like (ABC) diffuse large B-cell lymphoma (DLBCL), mantle cell lymphoma (MCL), and marginal zone lymphoma (MZL). Notably, the compound maintained its anti-tumor activity in MZL cell lines with acquired resistance to BTK and PI3K inhibitors, suggesting potential utility in treatment-resistant hematological malignancies and solid tumors.